DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$24.92
-0.03 (-0.12%)
▼
5d:
+2.13%
30d:
+6.4%
90d:
+29.12%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DNLI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DNLI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $24.92, which is considered extended relative to its 30-day fair value range of $23.30 to $24.88.
Technical Outlook: Technically, DNLI is in a strong uptrend. Immediate support is located at $24.01, while resistance sits at $25.70.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.44 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DNLI is in a strong uptrend. Immediate support is located at $24.01, while resistance sits at $25.70.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.44 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.30 -
$24.88
Company Quality Score
50/100
(HOLD)
Options IV Signal
9th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 9th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.2% below Wall St target ($35.44)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.30 -
$24.88
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.37
(5.5%)
Support & Resistance Levels
Support Level
$24.01
Resistance Level
$25.70
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.26
Wall Street Target
$35.44
(+42.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 4:49 PM ET
Data refreshes hourly during market hours. Next update: 5:49 PM
Data refreshes hourly during market hours. Next update: 5:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
